US FDA approves Vera's kidney disease drug

The FDA approved Vera Therapeutics' Trutakna, the first drug targeting BAFF and APRIL immune proteins for IgA nephropathy, a potentially fatal kidney disease, priced at $425,000 annually. The approval is based on phase 3 data showing 42% reduction in urinary protein versus placebo, entering a competitive market alongside Otsuka, Novartis, and Travere treatments.

This Wire brief sits within Fusion42's coverage of Digital Health.